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ABSTRACT 
The development of flexible drug delivery systems that can be tuned as a function of the drug 
to be delivered and of the target disease is crucial in modern medicine. For this aim, novel 
amphiphilic poly(-caprolactone)-g-poly(ethylene glycol) (PCL-g-PEG) with well controlled 
design were synthesized by thiol-yne photochemistry. The grafting density and copolymer 
amphiphilicity were easily controlled via the reaction parameters: concentration, reaction 
time, PEG length and molar ratio between PCL and PEG or photoinitiator in the reaction 
mixture. The self-assembling behavior of the copolymers was studied and a correlation 
between the composition of PCL-g-PEG and the nanoaggregate diameter sizes (28 to 73 nm) 
and critical aggregation concentration (1.1 to 4.3 mg/L) was found. The influence of 
copolymer amphiphilicity on the drug loading was evaluated with various drugs including 
anticancer drugs (paclitaxel, ABT-199), drugs to overcome multidrug resistance in cancer 
cells (curcumin, Elacridar), anti-inflammatory drug (dexamethasone) and antibacterial drug 
(clofazimine). Finally, the influence of amphiphilicity on curcumin release and toxicity 
towards MCF-7 cancer cell lines was studied. The impact of grafting density, PEG length and 
overall EG/CL ratio are discussed in detail. Curcumin loaded PCL-g-PEG with lower EG/CL 
ratios and shorter PEG chains showed higher toxicity compared to their more hydrophilic 
counterparts.  
 
KEYWORDS: graft poly(-caprolactone)-poly(ethyleneglycol) copolymers; micelles; 
nanoparticles; drug delivery; curcumin; amphiphilicity. 
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INTRODUCTION 
Amphiphilic copolymers self-assembling into micelles or nanoparticles play a key role in 
modern drug formulation strategies as a result of their capacity to protect and deliver drugs to 
the target site, e.g. tumors, with suitable pharmacokinetics.
1, 2
 Drug loaded self-assemblies 
provide many advantages compared to low-molecular-weight drugs as they can reduce drug 
toxicity towards healthy tissues and increase the drug stability and the efficacy of drugs by 
changing the pharmacokinetics to more favorable one. Among amphiphilic copolymers, 
aliphatic polyester-based copolymers, in particular PEG-b-PLA and PEG-b-PLGA diblock 
copolymers, have been widely studied due to their degradability and biocompatibility.
3, 4
 After 
many years of extensive research and development, some have finally been introduced to the 
market like the PEG-PLA-based Genexol
®5
 which paves the way for future products and 
confirms the potential of polyester-based drug delivery systems.  
 
Among the synthetic polyesters, poly(-caprolactone) (PCL)  is well-known for its 
biocompatibility, its slower hydrolytic degradation compared to PLA or PLGA, its ability to 
load drugs and its mechanical properties similar to classical polyolefins. These properties 
make it a valuable candidate for tissue engineering and medical devices.
6, 7
  However, the use 
of PCL is not limited to macroscopic systems and many examples of micro- or nanosystems 
for drug delivery, i.e. micelles and particles, are described in literature.
8
 All kinds of 
macromolecular architectures based on PCL and PEG have been proposed from classical 
diblock copolymers, to triblock copolymers, dendrimer-derived, star or miktoarm 
architectures.
9-13
 The variety of macromolecular architectures and compositions has proved 
the potential of these polymer systems for cancer therapy  and  the impact  of PCL-PEG 
copolymer amphiphilicity on the formation and shape of self-assemblies,
14, 15
 drug loading, 
formulation stability
12, 16
 and cellular internalization
17-19
 have been studied. It was also 
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demonstrated that PCL-PEG copolymers could act as modulators of drug efflux transporter 
P-glycoprotein in vitro, and therefore they could be of beneficial to the problematic 
treatment of multidrug resistance (MDR) cancer tumors.20 
 
In this context, graft copolymers are of particular interest, since their architecture allows an 
easy variation of the number of PEG chains along the polymer backbone and consequently of 
the resulting amphiphilicity. Graft copolymers also exhibit lower critical aggregation 
concentrations (CAC) compared to their linear analogs and they assemble into micelles with 
higher stability in serum and during freeze-drying process.
21, 22, 23, 24
 As a consequence various 
polyester-g-PEG have been synthesized to date following either the “grafting through” or 
“grafting to” strategies. However, most of them are lactide- or glycolide-based polyesters,25-28 
whereas only very little has been reported on PCL. For example, the group of Jerôme et al. 
synthesized PCL-g-PEG via the “grafting to” process by reacting azido-CL and alkynyl end-
capped PEG, by a CuAAC click chemistry approach.
29, 30
 A similar approach was utilized by 
Zhang et al.
31
 or by Parrish et al. with an -propargyl--valerolactone.32  A grafting through 
approach using a CL end-capped PEG that was copolymerized with CL was also proposed by 
Rieger et al.
33
 The main problem of these methods is the use of functional lactones whose 
synthesis is limited in terms of amount and whose polymerization can be problematic when 
high molecular weights are targeted. As a consequence, Coudane et al. proposed an 
alternative “grafting to” approach by using anionic post-polymerization modification of the 
carbonyl of a commercial PCL to graft chlorocarbonate PEG at the PCL -position.34, 35 This 
one pot method is rapid and versatile, and the graft copolymer was easily prepared on a 
multigram scale. However, the grafting density influencing the self-assembly behavior is not 
well-controlled. To overcome this limitation we recently synthesized PCL-g-PEG, thanks to 
the combination of a scale-up friendly anionic post-polymerization modification of PCL and a 
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subsequent grafting of PEG side chains via the fast and metal free photoradical thiol-yne 
reaction, which allowed an easy control of the copolymer amphiphilicity. The prepared PCL-
g-PEG polymers with EG/CL ratios ranging from 0.1 to 1.3 formed nanoparticles and frozen 
micelles of different hydrodynamic diameters. 
36
  
 
Hydrophilicity of the previously prepared systems was however quite low, resulting in 
pegylated nanoparticles with low PEG density rather than micelle-like nanoaggregates, which 
may limit the release properties. In addition, the impact of the copolymer 
hydrophilic/hydrophobic balance on the ability to deliver various drugs was not investigated. 
Here, a family of micelles-forming PCL-g-PEG with higher and controlled hydrophilicities 
(EG/CL ratios ranging from 2 to 5.5) is synthesized and characterized. The impact of 
amphiphilicity on the loading of various poorly soluble drugs, including anticancer drugs 
(paclitaxel, ABT-199), multidrug resistance targeting drugs (curcumin, Elacridar), anti-
inflammatory drug (dexamethasone) or antibacterial drug (clofazimine) is evaluated. Finally, 
impact of amphiphilicity on the curcumin release, and on the toxicity towards MCF-7 cancer 
cells is discussed. 
 
EXPERIMENTAL PART 
Materials 
PCL (Mn ≈ 45 kg mol−1), propargyl bromide (80 wt% in toluene), lithium diisopropylamide 
(LDA, 2 M in THF/heptane/ethylbenzene), 2,2-dimethoxy-2-phenylacetophenone (DMPA, 
>99%), p-toluenesulfonic acid (>99%), -caprolactone (-CL , >99%), PBS 1x, clofazimin 
and curcumin were purchased from Sigma-Aldrich (St-Quentin Fallavier, France). Paclitaxel 
was obtained from LC Laboratories (Woburn, United States). ABT-199, dexamethasone and 
elacridar were purchased from Sigma-Aldrich (Prague, Czech Republic). α-Methoxy,ω-
6 
 
hydroxyl poly(ethylene glycol) with Mn = 2000 and Mn = 5000 g/mol (PEG2k, PEG5k) were 
obtained from Sigma (St-Quentin Fallavier, France). α-Methoxy,ω-hydroxyl poly(ethylene 
glycol) with Mn = 750 g/mol (PEG0.7k) was obtained from Acros Organics (Noisy-le-Grand, 
France). Ascorbic acid (purissimum grade) was obtained from Riedel-de Haen. NH4Cl 
(>99%) was purchased from Acros Organics (Noisy-le-Grand, France), technical grade 
MgSO4 from Carlo Erba (Val de Reuil, France), and methanol (≥99.8%), dichloromethane 
(DCM, ≥99.9%), dimethylformamide (DMF, ≥99.8%), toluene (puriss) and anhydrous 
tetrahydrofuran (THF, ≥99.9%) from Sigma-Aldrich (St-Quentin Fallavier, France). THF was 
dried using a Pure Solv Micro Single Unit (Inert®) system. Toluene and -CL were distilled 
over CaH2 prior to use. Spectra/Por® dialysis tubes (cut-off, 6–8 kDa or 3.5 kDa) were 
obtained from Spectrum Labs. Amicon ultra centrifugal filter units (Ultra-15, 10 kDa) were 
purchased from Sigma Aldrich (Noisy-le-Grand, France).  
 
Characterizations 
NMR spectroscopy. 
1
H NMR spectra were recorded at room temperature using an AMX300 
Bruker spectrometer operating at 300 MHz. Deuterated chloroform and deuterated dimethyl 
sulfoxide were used as solvents, chemical shifts were expressed in ppm with respect to 
tetramethylsilane (TMS). Diffusion ordered spectroscopy (DOSY) experiments were 
performed on a Bruker Avance III spectrometer operating at 600 MHz, using deuterated 
dimethyl sulfoxide (DMSO) as solvent. 
Size exclusion chromatography (SEC) was performed on a Viscoteck GPC-Max VE 2001 
equipment fitted with a 2x30 cm long 5 µm mixed C PLgel columns and coupled with VE 
3580 RI detector and VE 3210 UV/Vis detector. The mobile phase was THF at 1 mL/min 
flow rate at 30°C. Typically, polymer (10 mg) was dissolved in THF (2 mL) and the resulting 
solution was filtered through a 0.45 µm Millipore filter before injection of 20 µL of filtered 
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solution. The number average molecular weight (Mn) and the dispersity (Ð) of the polymers 
were expressed according to calibration using polystyrene standards. 
Fluorescence measurements and CAC determination. The CAC of the copolymers was 
determined by fluorescence spectroscopy using pyrene as a hydrophobic fluorescent probe. 
Measurements were carried out on an RF 5302 Shimadzu spectrofluorometer (Japan) 
equipped with a Xenon light source (UXL-150S, Ushio, Japan). Briefly, an aliquot of pyrene 
solution (6×10
-6
 M in acetone, 1 mL) was added to different vials, and the solvent was 
evaporated. Then, 10 mL of aqueous solutions of different concentrations were added to the 
vials. The final concentration of pyrene in each vial was 6×10
-7
 M. After overnight 
equilibration at room temperature, the fluorescence excitation spectra of the solutions were 
recorded from 350 to 400 nm at an emission wavelength of 371 nm. The emission and 
excitation slit widths were 5 nm and 3 nm, respectively. The excitation fluorescence values at 
333.5 and 336.5 nm were used for subsequent calculations. The CAC was determined from 
the intersection of linear regression lines of the I336.5/I333.5 ratio versus polymer concentration 
plots. 
Light scattering measurements. Dynamic light scattering (DLS) was carried out with a 
Malvern Instrument Nano-ZS equipped with a He–Ne laser ( = 632.8 nm). Polymer 
solutions at 1.0 mg.mL
-1
 were filtered through a 0.45 µm PTFE microfilter before 
measurements. The correlation function was analyzed via the general purpose method 
(NNLS) to obtain the distribution of diffusion coefficients (D) of the solutes. The apparent 
equivalent hydrodynamic diameter (DH) was determined from the cumulant method using the 
Stokes–Einstein equation. Mean radius values were obtained from triplicate runs. Standard 
deviations were evaluated from hydrodynamic radius distribution. 
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UV-spectrometry was performed on a Perkin-Elmer Precisely Lambda 35 spectrometer, with 
1 cm optical path quartz cuvettes.  
 
Synthesis of PCL-g-PEG 
The PCL-yne/PEG-SH reactions were performed according to our previous work.
36
  In typical 
experiment, PCL-yne (100 mg; 8% alkyne groups with respect to CL units,        = 21300 
g/mol ; Ð = 2.4); and PEG2k-SH (820 mg; 6 eq. with respect to the alkyne group) were 
dissolved in DMF (10 mL) in a Schlenk flask (Table 1, entry 2). DMPA (9 mg; 0.5 eq.) was 
dissolved in DMF in another Schlenk flask covered by aluminium foil. The 2 flasks were 
purged with nitrogen for 10 min before closing with septums. The thiol-yne reaction medium 
was irradiated for 2 hours under UV light (100 mW/cm
2
) and DMPA was added by successive 
additions (4 times) with a syringe at fixed intervals over the reaction time. The mixture was 
then concentrated under vacuum and centrifuged in water by centrifugal filter units 10 kDa. 
Centrifugation was repeated until full removal of unreacted PEG chains. The solution was 
lyophilized and the product was analyzed by SEC to assure the absence of free PEG.  
1
H NMR (300 MHz; CDCl3): δ (ppm) = PCL backbone 4.0 (2H, CH2-O), 2.3 (2H, C(O)CH2), 
1.6 (4H, C(O)CH2–CH2–CH2– CH2–CH2–O), 1.3 (2H, C(O)CH2–CH2–CH2–CH2-CH2-O); 
PEG side chains 4.2 (2H, CH2COO), 3.5 (4H, CH2CH2O), 3.3 (3H, OCH3), 2.8 (2H, 
CH2SCH2), 2.6 (2H, COOCH2). 
 
Synthesis of PCL-b-PEG 
PCL-b-PEG was synthesized according to classical procedures. PEG5k was used a 
macroinitiator for the ring opening polymerization of CL in anhydrous toluene in the presence 
of SnOct2 as a catalyst (0.3 eq. with respect to PEG). Amounts of reactant were determined to 
yield the expected copolymer with EG/CL = 2.6, corresponding to blocks of 5000 g/mol for 
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PEG and for PCL. ROP was carried out for 48 hours at 100°C and was stopped by addition of 
few drops of HCL 1N. The mixture was then concentrated under vacuum prior to precipitation 
in diethylether. The resulting solid is further dissolved in water and centrifuged in water by 
centrifugal filter units 10 kDa. Centrifugation was repeated until full removal of unreacted 
PEG chains. The solution was lyophilized and the product was analyzed by SEC to assure the 
absence of free PEG.  
 
Preparation of nanoaggregates 
Blank and drug loaded PCL-g-PEG nanoaggregates  were prepared by the self-assembly 
method according to our previous article.
36
 Typically, drug (5 mg) and PCL-g-PEG (35 mg) 
were dissolved in 2 mL acetone. Then 5 mL of PBS were added. The mixture was stirred one 
hour using an Ultra-Turrax stirrer (8000 rpm). The remaining acetone was evaporated under 
vacuum. The solution was then centrifuged for 10 min at 3600 rpm and 20°C before filtration 
through a 0.45 μm filter to eliminate the unloaded drug. 
 
Determination of drug loading and encapsulation efficiency 
Drug loading (DL) and encapsulation efficiency (EE) were determined by UV/Vis 
spectrophotometry at 425 nm for curcumin, 468 nm for clofazimine and 410 nm for elacridar. 
Quantification of curcumin and clofazimine was performed with respect to a calibration curve 
in acetone / water (20:80). Quantification of elacridar was done using a calibration curve in 
acetone / water (80:20). Loading of dexamethasone and ABT-199 were determined by high 
performance liquid chromatography (HPLC, Shimadzu LC-20AD, Japan) instrument 
equipped with a column (Chromolith® Performance RP-18) and autosampler (SIL-20AC 
HT). Fluorescence and PDA detector (RF10AXL and SPD-M10AVP) were used for detection 
of the drugs. A gradient elution was applied to detect the dexamethasone and the ABT-199, a 
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linear gradient from 100% of a mixture (5% ACN (0.1% TFA) + 95% H2O (0.1% TFA)) till 
100% of a mixture (95% ACN (0.1% TFA) + 5% H2O (0.1% TFA) was used. Flow rate was 
set at 1 mL/min, detection wavelength was 240 nm for dexamethasone and 314 nm for ABT-
199. 
Quantification of paclitaxel (PTX) was done by HPLC (WatersTM 717plus Autosampler), 
equipped with C18 column and a water 2998 photodiode array detector (λmax PTX= 227 nm). 
The gradient elution applied was ACN/water: 50/50 for 2 min, then ACN/water: 75/25 until 
the 15
th
 min at 1 mL/min flow rate. PTX was extracted from copolymers before injection in 
HPLC as follows: 1 mL of PTX-loaded copolymer solution was added to 5 mL of water: 
DMF (50:50). After centrifugation in Spectra/por® dialysis tubes (cut-off, 6–8 kDa), the 
solvent was evaporated and the PTX was dried under vacuum. PTX was dissolved in a precise 
volume of ACN and quantified by HPLC.  
 
The DL content and EE were calculated based on the following formulae: 
DL (%) = 100 × (MD) / (MP + MD)  
EE (%) = 100 × (MD) / (MDi) 
with MD = mass of drug in nanoaggregates, MP = mass of copolymer and MDi = mass of drug 
initially added to prepare nanoaggregates. 
 
Drug release kinetics 
The release of curcumin from PCL-g-PEG nanoaggregates was assessed in phosphate buffer 
saline (PBS, pH 7.4) containing 0.1% w/v Tween 80 and 0.015% w/v ascorbic acid at 37 °C 
under constant orbital shaking (100 rpm ; Heidolph Unimax 1010). Tween is classically used 
to provide water-solubility to curcumin in such assays.
37-39
 Ascorbic acid is a biomolecule 
naturally present in plasma, which is used to enhance the stability and avoid the degradation 
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of the released curcumin.
40
 In a typical release study, 2 mL of Curcumin/PCL-g-PEG micellar 
solution were poured in a dialysis bag (cut-off 3.5 kDa) that was immerged in 20 ml of buffer 
solution at 37°C. At specific time points, the entire release medium was removed and replaced 
with 20 mL fresh buffer solution. Collected samples were analyzed by UV–Vis 
spectrophotometry at 425 nm with reference to a calibration curve of curcumin in acetone: 
water (20:80). The amount of released curcumin (Rc) was calculated based on the following 
formula: 
Rc (%) = 100 × (MRC) / (MC) 
with MRC = mass of released curcumin and  MC = mass of curcumin in nanoaggregates. 
 
Degradation of nanoaggregates 
7 mg of copolymers PCL-g-PEG0.7k1.2 and PCL-g-PEG2k5.4 were dissolved in 1 ml of 
acetone in a hemolysis tube, and then 5 ml of PBS were added. After evaporation of acetone, 
hemolysis tubes were put in an incubator at 37°c under stirring at 150 rpm. Tubes were 
removed after 1 week, 1 month, 3 months and 6 months. Samples were freeze-dried, the solid 
residue was dissolved in THF and the resulting solution was filtered before analysis by SEC. 
Degradation experiments were done in triplicates. 
 
In vitro assay against MCF7 cells 
Cell culture 
Human breast cancer cell lines MCF-7 were a gift of Dr. Garcia’s lab (IBMM, Team “Glyco 
et Nanovecteurs pour le ciblage thérapeutique”, Montpellier, France). Cells were maintained 
in DMEM-F12 supplemented with Fetal Bovine Serum (10%, v/v) and 1% 
penicillin/streptomycin at 37°C in a humidified incubator containing 5% CO2. 
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Cell cytotoxicity assay 
Cytotoxicity of the nanoparticles was measured in MCF-7 cells using Prestoblue® Cell 
viability reagent (Invitrogen). For this assay, cells were plated into a 24-well plate in amount 
of 1.5×10
4
 cells per well and allowed to attach overnight. They were then treated with 0.18 
and 18 µg/ml of free curcumin (dissolved in DMSO) or curcumin encapsulated (dissolved in 
PBS) for 24h and 48h. Appropriate equivalent amounts of nanoparticles without curcumin 
were run simultaneously. Medium containing equivalent amounts of DMSO or PBS or 
medium only were used as a control. Cell viability was measured using Prestoblue® Cell 
viability reagent according to manufacturer’s instruction. Briefly, 10% of Prestoblue® was 
diluted into cell growth medium. When added to cells, the reagent is modified by the reducing 
environment of the viable cells and turns red, becoming highly fluorescent. After incubation 
time, supernatant was transferred to a 96-well plate and the fluorescence was measured at 
560/590nm using a microplate reader (PerkinElmer, Victor3V). 
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RESULTS AND DISCUSSION 
Synthesis of graft copolymers with controlled amphiphilicity 
A convenient thiol-yne photo-addition methodology was used to synthesize the PCL-g-PEG 
copolymers and to modulate their amphiphilicity.  For sake of clarity, a schematic 
representation of the preparation and architecture of the PCL-g-PEG copolymers is provided 
(ESI, Scheme S1).  Indeed, as shown in our previous work, it is possible to easily control the 
PEG grafting density by playing with the reaction parameters.
36
 To evaluate the influence of 
PCL-g-PEG hydrophilicity on the copolymers potential as drug delivery systems, we targeted 
a broad range of hydrophilicity with molar ratios EG/CL in the range 1.9 to 5.4 (Table 1). 
 
Table 1. Synthesis of PCL-g-PEG with controlled composition using PCL-yne and PEG-SH 
Entry Copolymer 
PEG  
(eq.)
a 
DMPA 
 (eq.)
a 
DMF 
(mL) 
Time 
(h) 
EG/C
b 
Grafting 
efficiency 
(%)
c 
Mn
d
 
(g/mol) 
Ð 
1 PCL-g-PEG0.7k1.9 10 1 10 2 1.9 56 24700 2.0 
2 PCL-g-PEG2k2.8 6 0.5 10  2 2.8 28 25800 2.7 
3 PCL-g-PEG2k3.6 6 0.5 2  1 3.6 36 27000 1.8 
4 PCL-g-PEG2k4.5 6 0.5 2  2 4.5 45 25900 1.6 
5 PCL-g-PEG2k4.7 6 1 2  2 4.7 47 29000 1.8 
6 PCL-g-PEG2k5.0 6  2 2  2 5.0 50 30000 2.1 
a) equivalent with respect to alkyne groups; b) calculated from the peak integrations of 
1
H-
NMR spectra ; c) calculated by 
1
H NMR analysis based on the initial content of alkyne groups 
and the EG/CL ratio and considering diaddition on all alkyne groups as 100% grafting 
efficiency d) SEC analyses in THF, polystyrene standards. 
 
The increased number of composition and higher hydrophilicity of the novel PCL-g-PEG 
compared to our previously presented copolymers was obtained thanks to the precise control 
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of the reactant concentration, the reaction time, the PEG-SH molecular weight, the number of 
PEG equivalents, and the amount of photoinitiator. The ratio EG/CL in product was easily 
increased from 1.9 to 2.8 by replacing PEG0.7K by PEG2K (entries 1 and 2), despite a lower 
number of PEG chains and DMPA equivalents. As expected and in accordance with our 
previous study with benzyl mercaptan,
36 
higher grafting efficiency was obtained for the 
shorter PEG due to the limited steric hindrance and higher thiol-end group accessibility for 
PEG0.7K compared to PEG2K. The impact of the reactant concentration on the grafting 
density is significant as shown by the increase of EG/CL ratio from 2.8 to 4.5 for a 4 times 
lower solvent volume (entries 2 and 4). Moreover, reaction time played also significant role as 
EG/CL increased from 3.6 after 1 hour of reaction to 4.5 after 2 hours (entries 3 and 4). 
Finally, the equivalent number of DMPA has only a limited impact on EG/CL ratio: EG/CL 
varies from 4.5 to 5 despite a 4 folds increase of DMPA equivalents was used (entries 3-5). 
These results, in conjunction to the previously published, confirmed the simplicity of 
modulation offered by the photo thiol-yne approach to yield amphiphilic PCL-g-PEG 
copolymers that are easily turned from highly hydrophobic structures (EG/CL = 0.35, 
previous work) to more hydrophilic ones (EG/CL = 5).  
Molecular weights, measured by SEC, were in the range 25000 g/mol to 30000 g/mol (Ð =1.6 
to 2.7) and did not varied significantly for various copolymer. Further discussion of the 
molecular weights of the copolymers with respect to PCL-yne (       = 21200 g/mol Ð = 2.4) or 
comparison between the copolymers is not provided as hydrodynamic behavior of the 
copolymers is known to be strongly impacted by their amphiphilicity and architectures. In 
particular, underestimation of molecular weight of graft copolymers was reported in literature 
and is believed to be due to the impact of grafting density on hydrodynamic radius, which 
gives more compact structures than their linear counterparts.
26, 32
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Characterization of PCL-g-PEG nanoaggregates 
Critical aggregation concentrations (CAC) of PCL-g-PEGs  
Critical aggregation concentrations (CAC) of PCL-g-PEGs were calculated for all copolymers 
using the excitation spectra of pyrene.  Typical excitation spectra of pyrene solutions are 
shown in Figure S1 (Electronic Supplementary Information (ESI)) as a function of the 
concentration of PCL-g-PEG2k3.2. The intensities of excitation peaks at ex = 336.5 and 333.5 
nm, denoted I333.5 and I336.5 respectively, were chosen as the variation of the I336.5/I333.5 
intensity ratio is related to the self-association of amphiphilic PCL-g-PEGs and the partition 
of pyrene between the aqueous phase and the hydrophobic cores of micelles.
41
 CACs were 
estimated based on the tangents method and are listed in Table 2.  
 
Table 2. Grafting number, critical aggregation concentration (CAC) and size of blank 
nanoaggregates as a function of copolymer composition. 
Entry Copolymers EG/CL 
Grafting 
number
a
 
CAC 
(mg/L) 
Size
d 
(nm) 
PDI 
1
[36]
 PCL-g-PEG0.7k1.2 1.2 13
 
1.1
b 
32 0.24 
2 PCL-g-PEG0.7k1.9 1.9 21
 
3.5 42 ± 4 0.24 ± 0.01 
3 PCL-g-PEG2k2.3 2.3 9.5 2.6 nd. nd. 
4 PCL-g-PEG2k3.2 3.2 13 2.6 28 ± 1 0.21 ± 0.01 
5 PCL-g-PEG2k4.7 4.7 19 4.3 nd. nd. 
6 PCL-g-PEG2k5.4 5.4 22 4.3 73 ± 2 0.40 ± 0.00 
7 
PCL-b-PEG5k2.6
c 
2.6 1 17 59 ± 1 0.21 ± 0.01 
a) Number of PEG chains per PCL chain, calculated by 
1
H NMR analysis based on the 
molecular weight of PCL-yne and of PEG ; b) CAC of PCL-g-PEG1.2 was calculated in our 
previous work using the emission spectra of pyrene;
36
 c)
 
block copolymer ; d)
 
Mean size 
determined by DLS 
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CAC value was found to be strongly impacted by the composition (EG/CL) and grafting 
number (number of PEG chains per PCL backbone) of the copolymers. In more details, for 
entries 1 and 2, where PEG0.7K was used, CAC increased from 1.1 mg/L to 3.5 mg/L with 
the increase of hydrophilicity from EG/CL = 1.2 to EG/CL = 1.9, respectively. This is a 
classical result for amphiphilic self-assembling polymers. The same trend was obtained with 
PEG2K (Table 2, entries 3 to 6) where CAC varied from 2.6 to 4.3 mg/L for PCL-g-PEG2k2.3 
to PCL-g-PEG2k5.4. However, one can note that EG/CL ratio alone cannot explain the self-
assembling behavior of the graft copolymers. The grafting number has also a strong influence 
on the CAC. PCL-g-PEG with close architectures, ie. the same grafting number, presented 
similar CAC. This is clearly the case for PCL-g-PEG2k2.3 and PCL-g-PEG2k3.2 that have a 
similar CAC (2.6 mg/L), despite different EG/CL ratios due to the presence of ca. 10 PEG 
chains for both polymers. The same phenomenon is observed in PCL-g-PEG2k4.7 and PCL-g-
PEG2k5.4 (ca. 20 PEG chains). At similar EG/CL ratios, the general trend is therefore to 
observe a lower CAC for lower grafting number. This is confirmed by the comparison 
between PCL-g-PEG0.7k1.9 and PCL-g-PEG2k2.3. In this case, close EG/CL ratios are 
obtained but grafting numbers are very different with 21 PEG0.7k chains for PCL-g-
PEG0.7k1.9 against 9.5 PEG2k chains for PCL-g-PEG2k2.3. This leads to a lower CAC for the 
less substituted PCL-g-PEG2k2.3 although it presents the higher EG/CL ratio. In summary, we 
have found that all graft PCL-g-PEG copolymers showed low CAC values below 5 mg/L, 
whatever the composition and substitution degree.  
With aim to compare the graft copolymers with their linear block copolymers counterparts, a 
PCL5k-b-PEG5k diblock copolymer with EG/CL = 2.6 was synthesized. Despite similar 
EG/CL ratios, this linear copolymer had a much higher CAC (17 mg/L) than its counterpart 
PCL-g-PEG2k2.3 (2.6 mg/L). This result is in agreement with the literature where the lower 
CAC of grafts copolymers is assigned both to their higher polydispersity and to their reduced 
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mobility as a consequence of the steric hindrance induced by the side chains.
23, 24
 Results 
obtained for CAC values of all PCL-g-PEG graft copolymers are highly promising, showing 
that the formed nanoaggregates should be useable as drug delivery systems in medicine as no 
dissociation upon the high dilution encountered with injection is expected. 
 
Size of PCL-g-PEGs nanoaggregates 
All nanoaggregates have hydrodynamic diameters below 100 nm (Table 2) showing useable 
size for prolonged circulation in blood stream and subsequent accumulation and extravasation 
within the target place, e.g. solid tumor or place of inflammation. One should note that 
filtration prior to DLS analysis may have eliminated objects larger than 0.45 µm if present. 
The size of nanoaggregates is increased with the hydrophilicity, ie. EG/CL ratio and 
substitution degree, as exemplified by the comparison between PCL-g-PEG0.7k1.2 (DH = 32 
nm) and PCL-g-PEG0.7k1.9 (DH = 42 nm) based on PEG0.7K or between PCL-g-PEG2k3.2 
(DH = 28 nm) and PCL-g-PEG2k5.4 (DH = 73 nm) based on PEG2K. This is due to the higher 
hydration of the more hydrophilic shell in conjunction with an extended conformation of the 
PEG chains with increasing surface density of PEG. For increasing EG/CL ratios this result 
can also be explained by the presence of PEG chains stuck inside the nanoaggregates, which 
might imply a more swollen state for the core of the nanoaggregates. Polydispersity of the 
nanoaggregates is between 0.21 and 0.40. These rather high values are believed to result from 
the architecture of the graft copolymers that may presents inhomogeneity of repartition of the 
grafted PEG chains along the PCL backbone due to the thiol-yne strategy used (Scheme S1, 
ESI). It also results from the less controlled assembly of graft copolymers compared to 
classical hydrophilic diblock copolymers.  
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Stability of self-assemblies 
Degradation kinetics of the self-assemblies was evaluated under standard hydrolytic 
conditions over a 6 months period. For this purpose the two most different copolymers, 
namely PCL-g-PEG0.7k1.2 and PCL-g-PEG2k5.4, were selected to generate blank 
nanoaggregates. At predetermined degradation times, buffer solutions of nanoaggregates 
(PBS, pH 7.4, 37°C) were analyzed by SEC (Figure 1, ESI Table S1). Obviously, conditions 
were not intending to recreate in vivo degradation conditions where such systems are expected 
to be degraded faster as a consequence of the lower pH found in tumor tissues (cancer tissues 
pH 6.5-7.2) or specific cell components (endosomes 5.0-6.5, lysosomes 4.5-5.0)
42
 and of the 
presence of enzymes (lipases).
43
 We aimed to do a comparative study to evaluate the impact 
of copolymer amphiphilicity and architecture on the in vitro degradation rate.  
For both copolymers, release of PEG chains was witnessed. It results from the hydrolysis of 
the ester bond between the terminal hydroxyl-PEG group and the propionic acid used to 
prepare the PEG-SH. The first appearance of a peak corresponding to free PEG chains was 
seen after 1 month in the more hydrophobic PCL-g-PEG0.7k1.2 (Figure 1a) and after only 1 
week in the more hydrophilic PCL-g-PEG2k5.4 (Figure 1b). By comparison of the relative 
intensities of peaks after 3 and 6 months, it may be concluded that all PEG side chains were 
hydrolyzed after 3 months in PCL-g-PEG0.7k1.2, whereas PEG release continued between 3 
and 6 months in the more substituted PCL-g-PEG2k5.4. In summary, degradation starts earlier 
for the more hydrophilic copolymer, but due to a higher grafting number, it lasts over a longer 
period compared to the more hydrophobic copolymer. 
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Figure 1. Degradation of PCL-g-PEG copolymers in PBS (pH 7.4, 37°C) with a) EG/CL = 
1.2 and b) EG/CL = 5.4 (SEC analyses were run in THF) 
 
An additional comment should be done on the initial degradation period of the most 
hydrophobic copolymer. A high molecular weight population is formed after 1 week, still 
present after 1 month, to finally disappear after 3 months (Figure 1a, shoulder peak at ca. 15 
minutes). This is confirmed by DOSY-NMR analyses that also show the release of free PEG 
after 1 month (Figure 2). Different hypotheses can be done to explain this phenomenon. PCL-
g-PEG0.7k1.2 is substituted in average by 13 PEG0.7K chains (Table 2), whereas full 
substitution of the alkyne groups initially present on the PCL-yne would correspond to ca. 32 
PEG0.7K chains.  Some unreacted alkyne groups, and vinylsulfide groups (thiol-yne 
monoaddition) are therefore present in the copolymer. Rearrangements between these groups 
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leading to cyclic compounds have been reported in litterature.
44
 In a same manner, if 
considering the free alkyne groups and thioether groups, intramolecular chalcogenation has 
been reported following radical activation that may occur in our case due to the long 
exposition of degradation medium to day light.
45
 Finally, another photoactivated side reaction 
is the direct crosslinking of vinylsulfide under light during the degradation. Taking into 
account these reactions, it is clear that some rearrangements leading to cross-linked structures 
may occur in the copolymer during its degradation and can explain the appearance of a 
population with higher molecular weight. For longer degradation times these cross-linked 
structures are also degraded and a clear decrease of molecular weight, as well as a lower 
dispersity, is again observed. A more detailed study on this aspect is however beyond the 
scope of the present work and is under way. However, one should note that all components of 
the PCL-g-PEG nanoaggregates will be excreted (released short PEG chains), and/or 
degraded (hydrolysis of PCL backbone), and thus unwanted accumulation of the carrier 
structure is not anticipated. Based on the presented results we can therefore conclude that the 
PCL-g-PEG copolymer nanoaggregates are suitable candidates as long circulating drug 
reservoirs for treatment of diseases, which need a long term exposure of the drug in the body.  
 
Figure 2. DOSY-NMR spectra of PCL-g-PEG0.7k1.2 as a function of the degradation time in 
PBS (pH = 7.4) at 37°C. (DMSOd6, 600 MHz, black crosses correspond to DMSO and water)  
21 
 
Encapsulation of drugs 
Encapsulation of various API 
To evaluate the potential of the PCL-g-PEG copolymer family for drug delivery, various APIs 
have been loaded into the nanoaggregates. The selected drugs were diverse in nature and 
therapeutic targets: anticancer drugs (paclitaxel, ABT-199), candidate drugs to overcome the 
multidrug resistance in cancer cells (curcumin, elacridar), anti-inflammatory drug 
(dexamethasone) and antibacterial drug (clofazimine). These drugs have usually a low to very 
low solubility, in the range 0.3 g/L for clofazimine to less than 0.4 mg/L for ABT-199 (Table 
S2, ESI), their body distribution after injection is non-selective, thus reaching also healthy 
cells and organ and finally, they show strong side-effect driven toxicity. Despite these 
drawbacks, they are very potent drugs with for example, activities below the nanomolar range 
for ABT-199.
46
 It is therefore of interest to solubilize them, even at low dose, in drug delivery 
systems with the aim to highly increase their bioavailability, prolong their availability within 
the body while reducing significantly their side-effect toxicity. Changing of the 
pharmacokinetics is the key point to observe the better outcome of the treatment with selected 
drugs. For that purpose, two above described copolymers with different hydrophilicities 
(EG/CL = 1.2 or 3.2) and forming in the aqueous solution nanoaggregates have been chosen 
for preparation of loaded polymer-based drug nanoaggregates.  
For all drugs, higher encapsulation efficiency and higher drug loading were obtained with the 
more hydrophobic copolymer, as expected (Table 3). The EE was lowered by 22% (curcumin) 
to 55% (ABT-199, Dexamethasone) by changing PCL-g-PEG0.7k1.2to PCL-g-PEG2k3.2. 
Coming to more details, in the case of paclitaxel, the EE was considered too low (< 3 wt%) 
and DL was not calculated. Similarly, other polyester-based drug delivery systems have 
shown low efficiency in paclitaxel formulation when using self-assembly method and large 
quantities of polymer with respect to PTX (100:1) were therefore required.
47
 On the opposite, 
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very high EE (92 wt%) and DL (12.1 wt%) were obtained with curcumin. The same 
phenomenon was observed for clofazimine that was loaded at 11.7 wt% in the copolymer. 
Finally, ABT-199 and Elacridar loadings were found very low (1.3 wt% and 2.6 wt%). 
Nevertheless, these drugs are extremely potent and are still under deep pharmaceutical 
development and evaluation. We suppose that even quite low DLs might be enough to witness 
a therapeutic effect because of the highly improved pharmacokinetic profile and prolonged 
accessibility of the drug within the body.  
 
 
Table 3. Encapsulation efficiency (EE) and drug loading (DL) of various APIs. 
 
Copolymer 
Paclitaxel ABT-199 Curcumin Elacridar Dexamethasone Clofazimine 
EE 
(wt%) 
DL 
(wt%) 
EE 
(wt%) 
DL 
(wt%) 
EE 
(wt%) 
DL 
(wt%) 
EE 
(wt%) 
DL 
(wt%) 
EE 
(wt%) 
DL 
(wt%) 
EE 
(wt%) 
DL 
(wt%) 
PCL-g-
PEG0.7k1.2 
2.9 nd. 6.8 1.3 92.0 12.1 16.4 2.6 27.2 4.4 48.5 11.7 
PCL-g-
PEG2k3.2 
1.6 nd. 3.2 0.1 70.1 10.6 12.3 2 12.2 2.1 nd. nd. 
 
 
Encapsulation of curcumin 
Based on the high EE and DL values obtained with curcumin, further experiments were 
carried out using this drug. Curcumin is a naturally occurring drug that exhibits potent anti-
inflammatory, anti-oxidant, anti-bacteria, anti-virus, anti-tumor and antilipidemic activities.
48, 
49
 However, it has a poor solubility and poor oral bioavailability. Therefore, a water-based 
formulation based on graft copolymers allowing a tunable and controlled release would be of 
interest. In order to evaluate if the modulation of curcumin loading and release can be 
achieved using PCL-g-PEG, copolymers with different amphiphilicities were tested. Lower 
EEs and DLs with high hydrophilic copolymer were confirmed, EE decreasing from 92 wt% 
to 58 wt% and DL decreasing from 12.1 wt% to 8.2 wt% in PCL-g-PEG0.7k1.2 and PCL-g-
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PEG2k5.4,  respectively (Table 4, entries 1 and 7). Roughly, three ranges of amphiphilicity can 
be drawn out of these results with similar EE and DL for each range: EE ≈ 90 wt% and DL ≈ 
12 wt% for EG/CL ≤ 2  (entries 1-3); EE ≈ 70 wt% and DL ≈ 10 wt% for 2 ≤ EG/CL ≤ 3.5-4 
(entries 4-5); and EE ≈ 55 wt% and DL ≈ 8-9 wt% for EG/CL ≥ 4.5 (entries 6-7). This shows 
the importance of the EG/CL ratio that impacts the resulting conformation of nanoaggregates. 
As the amount of PEG is increased, higher amount of PEG chains are stuck into the structure 
of the nanoaggregates, resulting in a much less hydrophobic core, which does not represent a 
good environment to encapsulate hydrophobic drugs.  
 
Coming to the comparison between linear and graft copolymers, no influence of the 
architecture was found for a same EG/CL ratio (EG/CL = 2.6, entries 1 and 8). Similar EE 
and DL were obtained for PCL-g-PEG2k2.6 (PCL = 21300 g/mol ; PEG = 2000 g/mol) and 
PCL-b-PEG5k2.6 (PCL = 5000 g/mol ; PEG = 5000 g/mol). For comparison lower molecular 
weights PCL-b-PEG copolymers with a same EG/CL = 2.6 ratio are reported in literature for 
the encapsulation of curcumin. Liu et al. synthesized PCL2k-b-PEG2k and prepared 
curcumin-loaded polymer micelles by solid dispersion method.
38
 DL and EE were 
respectively 14.8 ± 0.1 wt% and 98.9 ± 0.7 wt%. Same results were reported by Song et al. 
(PEG2.4k-PCL2.4k)
50
 and Gou et al. (PEG2k-PCL2k)
51
 who used thin-film hydration or 
nanoprecipitation methods for micelles preparation, respectively. These values are higher than 
the ones obtained with PCL-g-PEG2k2.6. This can be explained by both the encapsulation 
method (thin film hydration or solid dispersion method vs. self-assembly method) and the 
lower molecular weight of the reported diblock copolymers (< 5000 g/mol vs. > 10000 
g/mol).  
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Table 4. Curcumin encapsulation efficiency (EE), drug loading (DL) and sizes of 
nanoaggregates as a function of PCL-g-PEG copolymer amphiphilicity. 
Entry Copolymer 
EE 
(wt%) 
DL 
(wt%) 
Size
a 
(nm) 
PDI 
1 PCL-g-PEG0.7k1.2
 
92.0 12.1 40 0.28 
2 PCL-g-PEG0.7k1.9
 
89.4 ± 7 11.6 ± 0.4 42 ± 6 0.29 ± 0.03 
3 PCL-g-PEG2k2.3 90.8 ± 8.8 11.7 ± 0.6 23 ± 2 0.13 ± 0.01 
4 PCL-g-PEG2k2.6 75.3 ± 5.5 10.0 ± 0.6 26 ± 4 0.30 ± 0.05 
5 PCL-g-PEG2k3.2 70.1 ± 8 10.6 34 ± 1 0.24 ± 0.01 
6 PCL-g-PEG2k4.9 56.0 ± 2.6 9.4 ± 0.7 51 ± 7 0.50 ± 0.10 
7 PCL-g-PEG2k5.4 57.8 ± 5.4 8.2 ± 1.2 48 ± 4 0.43 ± 0.03 
8 PCL-b-PEG5k2.6 80.3 ± 9.9 10.7 ± 0.9 56 ± 3 0.22 ± 0.04 
a) Mean size determined by DLS 
Size of curcumin loaded nanoaggregates was in the range 23 nm to 56 nm for all copolymers. 
Curcumin loaded samples were slightly larger than the blank nanoaggregates, except for the 
more hydrophilic copolymer PCL-g-PEG2k5.4 whose average size decreased from 73 to 48 
nm. It may be due to the fact that curcumin strongly interacts with PCL,
51
 which may induce a 
more compacted structure of the initially looser and more swollen nanoaggregates obtained 
with the most hydrophilic copolymer. As for the blank nanoaggregates (Table 2), and for the 
same reasons, the trend was that larger loaded nanoaggregates were obtained for the more 
hydrophilic copolymers. Polydispersity of drug loaded samples was large and not very 
different to the one of non-loaded samples showing that curcumin as low influence on the 
nanoaggregation behavior of the copolymers. This absence of influence is due to the less 
controlled self-aggregation of the graft copolymers and, for the lower EG/CL ratios, to the 
rapid folding of the hydrophobic core. One should note that for graft copolymers, a low extent 
of larger aggregates (< 30% in DLS intensity mode) is found with sizes between 100 and 200 
nm depending on the copolymer. This was not observed with the well-defined linear PCL-b-
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PEG5k2.6 giving of a more dynamic and homogenous system with better self-assembly 
compared to the uncontrolled self-aggregation of the graft copolymers. Noteworthy, PCL-g-
PEG2k2.6 (Mn ≈ 25000 g/mol) yielded nanoaggregates with DH ≈ 26 nm, ie.of the same size as 
the micelles generated from low molecular weight PCL-b-PEG2k2.6 (Mn ≈ 4000-5000 
g/mol).
50, 51
 For comparison, PCL-b-PEG5k2.6 with Mn = 10000 g/mol yielded larger micelles 
of DH ≈ 55 nm. This is due to a strong folding of the high molecular weight PCL backbone in 
PCL-g-PEG2k2.6.   
 
Release of curcumin  
Depending on the stability of the micelles, drugs can be released following the 
disruption/desintegration of the micelles and/or by diffusion. In the case of stable polymeric 
micelles, diffusion may be slow if favorable interactions exist between the drug and the core 
of micelles. To evaluate the impact of the copolymer composition on the drug release, 
curcumin–loaded PCL-g-PEG nanoaggregates with EG/CL = 1.9, 2.6 and 5.4 were prepared. 
In vitro drug release was studied in PBS containing 0.1 wt% Tween 80 and 0.015 wt% 
ascorbic acid. Results are summarized in Figure 3. No burst effect was observed and results 
showed similar kinetics profiles during the first 3 days with ca. 10% of the curcumin payload 
being released. Following this initial period, and as expected, the release was faster for 
nanoaggregates with higher hydrophilicity. 30% of curcumin payload was released in 20 days 
with PCL-g-PEG0.7k1.9 , instead of 45% and 55% with PCL-g-PEG2k2.6 and PCL-g-PEG2k4.9, 
respectively. Profiles were very similar for the two copolymers PCL-g-PEG2k2.6 and PCL-g-
PEG2k4.9. This was confirmed by the curves fits that were calculated using the CurveExpert 
1.40 software (Microsoft Coorporation 1993) to estimate the maximal release that could be 
reached with the copolymers (Figure S2a-d, ESI). Release is plateauing at ca. 40% after 40 
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days for PCL-g-PEG0.7k1.9 but reaches 69% and 72% for PCL-g-PEG2k2.6 and PCL-g-
PEG2k4.9, respectively, after 60 days.  
Similar release profiles were obtained with PCL-g-PEG2k2.6 and PCL-b-PEG5k2.6 copolymers 
(Figure 3, inset). The two architectures showing the same drug loading and release capacities, 
their main difference is therefore the smaller size of the nanoaggregates in the graft 
copolymer (DH ≈ 26 nm) compared to the ones obtained from the linear block copolymer (DH 
≈ 55 nm). This is not the case for the block copolymers with the same EG/CL = 2.6 ratios but 
with lower molecular weight. A 21% release was reported after 24h for PEG2k-PCL2k 
diblocks, and ca. 50% release after 7 to 9 days.
38, 51
 For comparison, similar ratios were 
obtained after 5 days and ca. 20 days with the graft copolymer PCL-g-PEG2k2.6. 
Based on the results obtained during our study, we can conclude that our nanoaggregates are 
able to release their payload in a controlled manner, which is depending on the hydrophilicity 
of the used PCL-g-PEG. It is worth to mention that although the reported release kinetics may 
appear slow, the situation in the body is slightly different. First, as nanoaggregates are 
circulating in the body the released drug is immediately redistributed, thus the release kinetics 
will be the most probably significantly higher. Second, in the frame of cancer therapy such 
nanoaggregates are expected to rapidly accumulate in the tumor tissue due to the EPR effect, 
where their payload will be more rapidly released that in vitro due to the faster in vivo 
degradation of copolyesters under the more acidic tumor environment. 
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Figure 3. Cumulative release of curcumin from PCL-g-PEG nanoaggregates as a function of 
EG/CL ratio. Inset corresponds to the comparison between PCL-g-PEG2k2.6 and PCL-b-
PEG5k2.6 copolymers. (Data are expressed as means ± SD and correspond to measurements in 
triplicate)  
 
Toxicity of curcumin loaded nanoaggregates 
Curcumin loaded PCL-g-PEG nanoaggregates were tested against breast cancer cell line 
MCF-7. All tests were performed with associated controls to check the non-toxicity of the 
various culture media used in cytotoxicity tests. In more details, the effect of a few percents of 
PBS in the culture medium has been assessed as the buffer is used to prepare the 
nanoaggregates suspensions prior to cell seeding. The same protocol was used with less than 
0.1% of DMSO as cosolvent to ensure the solubility of the free curcumin in the culture 
medium in accordance with previous studies.
52
 All media showed no toxicity (Figure S3, 
ESI). In a first assay, dose dependence viability of MCF-7 cells after 24h treatment was tested 
with the hydrophobic PCL-g-PEG0.7k1.2 to confirm the non-toxicity of unloaded 
nanoagreggates, and to evaluate the toxicity of curcumin-loaded micelles with a range of 
curcumin concentration between 0.18 and 18 µg/mL. These concentrations were selected 
from the literature.
52
 Figure 4a confirms the absence of cytotoxicity of the unloaded 
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nanoaggregates. The pertinence of the range of drug concentration was also confirmed with 
significant differences being obtained in terms of cells viability at low (0.18 µg/mL) and high 
((18 µg/mL) curcumin doses (Figure 4b). In addition, equivalent cytotoxicities towards the 
MCF-7 cells were observed for the same dose of curcumin, free or entrapped in the 
nanoaggregates, which confirmed the activity of the drug released from the PCL-g-PEG 
nanoaggregates. In more details, calculated IC50 values for free curcumin and curcumin-
loaded nanoaggregates were very close with values of 3 µg/mL and 5.5 µg/mL, respectively. 
 
Figure 4. Dose dependence viability of MCF-7 cells after 24h treatment (a) with blank 
nanoaggregates (concentration of nanoaggregates corresponds to the quantity required to 
encapsulate the determined dose of curcumin in the range 0.18 to 18µg/mL) and (b) with free 
curcumin (squares) or curcumin loaded PCL-g-PEG0.7k1.2 nanoaggregates (diamonds). 
(concentrations corresponds to µg/mL of curcumin in the culture medium and data are 
expressed as means ± SD and correspond to measurements in triplicate) 
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Based on these results, curcumin concentrations of 0.18 µg/mL (medium viability) and 18 
µg/mL (low viability) were selected to evaluate the impact of the copolymer amphiphilicity 
on their cytotoxicity towards MCF-7 cells. Four copolymers with EG/CL ratios ranging from 
1.9 to 5.4 were tested. The amount of loaded nanoaggregates added to the culture medium 
was adjusted based on the calculated drug loadings (Table 4) to provide the selected 
concentrations of curcumin. Control experiments with blank nanoaggregates were run in 
parallel. After treatment with blank micelles for 24 h and 48 h, cells viability was above 90% 
through the whole range of concentrations examined during the treatment, which confirmed 
the non-toxicity of the various copolymers for all EG/CL ratios (Figure S4, ESI). In other 
words, copolymers had no activity and effect on the cytotoxicity determination of curcumin 
loaded in nanoaggregates. MCF-7 cells viability was then evaluated in the presence of 
curcumin-loaded nanoaggregates as shown in Figure 5. 
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Figure 5. In vitro cell cytotoxicity of curcumin and curcumin-loaded nanoaggregates as a 
function of the PCL-g-PEG copolymer amphiphilicity after (a) 24 h and (b) 48 h. (Data are 
expressed as means ± SD and correspond to measurements in triplicate) 
 
After 24h cell viabilities were in the range 30 to 40% for all formulations, including free 
curcumin. However, at the lower dose of 0.18 µg/mL the most hydrophobic copolymer PCL-
g-PEG0.7k1.9 yielded the highest cytotoxicity. After 48h of treatment cells viability was only 
60% for PCL-g-PEG0.7k1.9 whereas all other formulations were not cytotoxic. These results 
show a higher cytotoxicity towards MCF-7 cancer cells for the most hydrophobic copolymer. 
At low curcumin dose, a strong increase of activity is gained from the use of the PCL-g-
PEG0.7k1.9 copolymer compared to free curcumin. Considering the drug release profiles 
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(Figure 3), the observed differences cannot be ascribed to higher curcumin content in the 
culture medium as all copolymers would release the same amount of their payload after 48h 
(~ 7%). The difference of activity is therefore based on differences in the PCL-g-PEG 
composition, architecture, and consequently on different amphiphilicity of the various 
nanoaggregates. Cellular uptake dependence over these factors is believed to be involved 
here. It was previously reported a higher cellular uptake for hydrophobic PEG2k- or PEG5k-
PLA block and miktoarm copolymers with EG/LA > 2.5,
17
 whereas some others reported the 
invert effect for PEG2k-PCL block copolymers with EG/CL < 2.5.
19
 This discrepancy of 
interpretations demonstrates the difficulty to link the cytotoxic effect of drug loaded vectors 
with a single parameter. Beside pure release parameters, the resulting cytotoxicity depends on 
many factors that can influence the endocytosis pathways, such as particle size, morphology, 
surface charge, and of course the amphiphilicity of the copolymers.  
 
Scheme 1. Relative cytotoxicity of curcumin loaded nanoaggregates as a function of the 
EG/CL ratio, grafting number and PEG molecular weight. 
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In the present study, the higher efficiency of PCL-g-PEG0.7k1.9  over its grafted counterparts 
is mainly related to the PEG chain length rather than the pure amphiphilic balance, the 
nanoaggregates sizes or the grafting number as supported by the following points. First, 
despite very different EG/CL ratios, all copolymers lead to loaded nanoaggregates of similar 
sizes (ca. 40 nm in diameter), which implies that size is not a critical factor. Second, 
considering the average grafting number, one should note that the grafting number of PCL-g-
PEG0.7k1.9 and PCL-g-PEG2k5.4 is ~20instead of 10 in PCL-g-PEG2k3.2. Despite these twice 
lower grafting number and lower hydrophilicity, curcumin-loaded PCL-g-PEG2k3.2 
nanoaggregates behave like PCL-g-PEG2k5.4 in terms of cells cytotoxicity. In the studied 
EG/CL range, nanoaggregates with shorter PEG chains allow improved cell membranes 
interactions which results in better cellular uptake; as illustrated in Scheme 1.  
This is confirmed by the dissipative dynamics simulation study carried out by Zhang et al.
18
 
They investigate how nanoparticles coated with different amphiphilic copolymers penetrate 
the cells as a function of the entry force and penetration force needed to cross the cell 
membrane. Hydrophobicity, hydrophilic/hydrophobic blocks repartition but also rigidity of 
the polymer presented to the membrane had a strong impact. Rigid copolymers showed better 
capability and need less time to pass through the cell membrane. This is in total accordance 
with our findings where shorter, more rigid and less hydrophilic PEG0.7k segments are 
expected to require less energy to pass through the cell membrane compared to PEG2k ones. 
An in depth study based on fluorescence microscopy will be undertaken in a future work to 
elucidate this particular point.  
Finally, the importance of the architecture is clearly visible when comparing block and graft 
copolymers. Based on the PEG molecular weight and EG/CL ratio, one might expect a lower 
efficiency for the PCL-b-PEG5k2.6 diblock copolymer but it is comparable to the PCL-g-
PEG0.7k1.9 graft copolymer. The polymer rigidity might again be a critical factor here.  
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In summary, the modulation offered by our synthetic approach for PCL-g-PEG copolymers 
offers great opportunities and a high potential for efficient DDS with high cytotoxicity against 
selected MCF-7 cancer cell line.  
Of course to prove the applicability of our nanoaggregates as DDS further investigation is 
needed and under way both in terms of formulation and freeze-drying of the DDS and in 
terms of in vivo applicability. However, considering the obtained results, it is our belief that 
the proposed PCL-PEG graft copolymers represent a good alternative to the classical diblock 
copolymers. Although the later might appear to date as more viable economically, PCL-PEG 
graft copolymers have various advantages compared to their linear counterparts. First, their 
CAC is about 10 times lower, which is of importance for formulation and economic reasons. 
Second, although minor populations of larger aggregates are obtained with the graft 
copolymers, they present more compact structures with twice lower hydrodynamic diameters 
compared to their linear counterparts, which may be of benefit for tissue penetration. Last but 
not least, the proposed PCL-PEG graft copolymers present the main advantage of being 
tunable, depending on the target application. When diblock copolymers can only be 
functionalized on their chain ends, graft copolymers obtained by thiol-yne approach, thanks to 
the presence of unreacted alkyne groups (cf. grafting efficiency), could be further modified 
with higher substitution degrees or with multifunctionalities. This particular point should be 
the matter of future work. 
 
CONCLUSION 
In this work, the easy modulation offered by the photo thiol-yne approach to generate 
amphiphilic copolymers was shown. PCL-g-PEG copolymers whose amphiphilicity was 
easily tuned from hydrophobic (EG/CL = 1.9) to hydrophilic (EG/CL = 5.4) have been 
synthesized. Their CAC is low, in the range 1 to 5 mg/L, it increased with the increase of 
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hydrophilicity. The grafting number was found to be critical for the CAC as PCL-g-PEG with 
the same grafting number present similar CAC values independently of the EG/CL ratio. 
Nanoaggregates were easily loaded with various drugs with DL being dependent on the APIs. 
Best results were obtained with curcumin that could be loaded at 12 wt%. The curcumin 
loaded nanoaggregates present sizes in the range 23 nm to 55 nm for all copolymers. All 
curcumin release curves present no burst effect although a faster release is obtained from the 
nanoaggregates with higher hydrophilicity. Finally, in terms of cytotoxicity against MCF-7 
cells, PCL-g-PEG0.7k1.9 is a better DDS candidate due to a combination of higher 
hydrophobicity and shorter PEG chains that may lead to a better cellular uptake in vitro. Of 
course the selection of suitable candidates for treatment of selected deseases has to be based 
on in vivo evaluation and we believe that the results summarized in the present paper could be 
usable for the selection of polymer nanoaggregates for future preliminary in vivo experiments.   
 
ELECTRONIC SUPPLEMENTARY INFORMATION (ESI)  
Scheme S1. Schematic representation of the preparation of the PCL-g-PEG copolymers by 
thiol-yne approach. 
Figure S1. Excitation spectra of pyrene as a function of the concentration of PCL-g-PEG2k3.2; 
Figure S2. Fit curves for the curcumin release from PCL-g-PEG copolymers; Figure S3. 
Viability of MCF-7 cells in different media; Figure S4. Viability of MCF-7 cells in the 
presence of non-loaded nanoaggregates; Table S1. SEC analysis of PCL-g-PEG during 
degradation; Table S2. Chemical structure and solubility parameters of tested APIs.  
 
ACKNOWLEDGMENTS  
The authors wish to thank the Azm & Saade Association for Assala Al Samad’s PhD 
fellowship, Prof. Rachid Makhloufi from the Institut Français Prague as well as Campus 
France for Eva Koziolová’s internship (Prisme Project 185CZEB160040), Stéphane Dejean 
35 
 
for 
1
H NMR analyses and Aurélien Lebrun of the Laboratoire de mesures physiques (LMP)-
University Montpellier 2 for DOSY NMR analyses. The work was also supported by the 
Ministry of Education, Youth and Sports of CR within the National Sustainability Program I 
(NPU I), Project POLYMAT LO1507 and Grant Agency of the Czech Republic (grant 15-
02986S). 
 
NOTES AND REFERENCES  
1. G. S. Kwon and K. Kataoka, Advanced Drug Delivery Reviews, 2012, 64, 237-245. 
2. H. Otsuka, Y. Nagasaki and K. Kataoka, Advanced Drug Delivery Reviews, 2012, 64, 
246-255. 
3. G. Gaucher, R. H. Marchessault and J. C. Leroux, Journal of Controlled Release, 
2010, 143, 2-12. 
4. J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz and P. Couvreur, Chem Soc Rev, 
2013, 42, 1147-1235. 
5. V. Weissig, T. K. Pettinger and N. Murdock, Int J Nanomed, 2014, 9, 4357-4373. 
6. A. L. Sisson, D. Ekinci and A. Lendlein, Polymer, 2013, 54, 4333-4350. 
7. M. A. Woodruff and D. W. Hutmacher, Prog Polym Sci, 2010, 35, 1217-1256. 
8. T. K. Dash and V. B. Konkimalla, Journal of Controlled Release, 2012, 158, 15-33. 
9. F. Bahadori, A. Dag, H. Durmaz, N. Cakir, H. Onyuksel, U. Tunca, G. Topcu and G. 
Hizal, Polymers-Basel, 2014, 6, 214-242. 
10. X. Gao, B. L. Wang, X. W. Wei, W. Rao, F. Ai, F. Zhao, K. Men, B. W. Yang, X. Y. 
Liu, M. J. Huang, M. L. Gou, Z. Y. Qian, N. Huang and Y. Q. Wei, Int J Nanomed, 
2013, 8, 971-982. 
11. S. A. Senevirathne, K. E. Washington, M. C. Biewer and M. C. Stefan, J Mater Chem 
B, 2016, 4, 360-370. 
36 
 
12. M. Ukawala, T. Rajyaguru, K. Chaudhari, A. S. Manjappa, S. Pimple, A. K. Babbar, 
R. Mathur, A. K. Mishra and R. S. R. Murthy, Drug Deliv, 2012, 19, 155-167. 
13. K. Yoon, H. C. Kang, L. Li, H. Cho, M. K. Park, E. Lee, Y. H. Bae and K. M. Huh, 
Polymer Chemistry, 2015, 6, 531-542. 
14. Z. X. Du, J. T. Xu and Z. Q. Fan, Macromolecular Rapid Communications, 2008, 29, 
467-471. 
15. E. A. Simone, T. D. Dziubla, F. Colon-Gonzalez, D. E. Discher and V. R. 
Muzykantov, Biomacromolecules, 2007, 8, 3914-3921. 
16. R. S. Lee and Y. T. Huang, Polymer Journal, 2010, 42, 304-312. 
17. C. Garofalo, G. Capuano, R. Sottile, R. Tallerico, R. Adami, E. Reverchon, E. 
Carbone, L. Izzo and D. Pappalardo, Biomacromolecules, 2014, 15, 403-415. 
18. L. Y. Zhang, M. Becton and X. Q. Wang, Journal of Physical Chemistry B, 2015, 119, 
3786-3794. 
19. Z. Zhang, Q. Q. Qu, J. R. Li and S. B. Zhou, Macromol Biosci, 2013, 13, 789-798. 
20. P. Elamanchili, C. Mceachern and H. Burt, J Pharm Sci-Us, 2009, 98, 945-958. 
21. C. Hoskins, P. K. Thoo-Lin and W. P. Cheng, Therapeutic delivery  2012, 3, 59-79    
22. J. Logie, S. C. Owen, C. K. McLaughlin and M. S. Shoichet, Chem Mater, 2014, 26, 
2847-2855. 
23. Z. S. Gao and A. Eisenberg, Macromolecules, 1993, 26, 7353-7360. 
24. C. L. Lo, C. K. Huang, K. M. Lin and G. H. Hsiue, Biomaterials, 2007, 28, 1225-
1235. 
25. F. Coumes, V. Darcos, D. Domurado, S. M. Li and J. Coudane, Polymer Chemistry, 
2013, 4, 3705-3713. 
26. X. Jiang, E. B. Vogel, M. R. Smith and G. L. Baker, Macromolecules, 2008, 41, 1937-
1944. 
37 
 
27. X. W. Jiang, M. R. Smith and G. L. Baker, Macromolecules, 2008, 41, 318-324. 
28. S. Onbulak, S. Tempelaar, R. J. Pounder, O. Gok, R. Sanyal, A. P. Dove and A. 
Sanyal, Macromolecules, 2012, 45, 1715-1722. 
29. H. Y. Li, R. Riva, R. Jerome and P. Lecomte, Macromolecules, 2007, 40, 824-831. 
30. R. Riva, P. Schmeits, F. Stoffelbach, C. Jerome, R. Jerome and P. Lecomte, Chem 
Commun, 2005, DOI: Doi 10.1039/B5102182k, 5334-5336. 
31. K. Zhang, Y. Wang, W. P. Zhu, X. D. Li and Z. Q. Shen, Journal of Polymer Science 
Part a-Polymer Chemistry, 2012, 50, 2045-2052. 
32. B. Parrish, R. B. Breitenkamp and T. Emrick, J Am Chem Soc, 2005, 127, 7404-7410. 
33. J. Rieger, P. Dubois, R. Jerome and C. Jerome, Langmuir, 2006, 22, 7471-7479. 
34. J. Coudane, E. Laurent and M. Vert, Macromolecular Rapid Communications, 2004, 
25, 1865-1869. 
35. S. Ponsart, J. Coudane, J. McGrath and M. Vert, J Bioact Compat Pol, 2002, 17, 417-
432. 
36. A. Al Samad, Y. Bakkour, C. Fanny, F. El Omar, J. Coudane and B. Nottelet, Polymer 
Chemistry, 2015, 6, 5093-5102. 
37. X. Gao, F. J. Zheng, G. Guo, X. X. Liu, R. R. Fan, Z. Y. Qian, N. Huang and Y. Q. 
Wei, J Mater Chem B, 2013, 1, 5778-5790. 
38. L. Liu, L. Sun, Q. Wu, W. Guo, L. Li, Y. Chen, Y. Li, C. Y. Gong, Z. Qian and Y. Q. 
Wei, Int. J. Pharm., 2013, 443, 175-182. 
39. H. Danafar, K. Rostamizadeh, S. Davaran and M. Hamidi, Drug Dev Ind Pharm, 
2014, 40, 1411-1420. 
40. Y. J. Wang, M. H. Pan, A. L. Cheng, L. I. Lin, Y. S. Ho, C. Y. Hsieh and J. K. Lin, J 
Pharmaceut Biomed, 1997, 15, 1867-1876. 
38 
 
41. M. Wilhelm, C. L. Zhao, Y. C. Wang, R. L. Xu, M. A. Winnik, J. L. Mura, G. Riess 
and M. D. Croucher, Macromolecules, 1991, 24, 1033-1040. 
42. Y. Cao, J. Q. Zhao, Y. M. Zhang, J. F. Liu, J. J. Liu, A. J. Dong and L. D. Deng, Rsc 
Adv, 2015, 5, 28060-28069. 
43. X. W. Wei, C. Y. Gong, M. Y. Gou, S. Z. Fu, Q. F. Guo, S. Shi, F. Luo, G. Guo, L. Y. 
Qiu and Z. Y. Qian, International Journal of Pharmaceutics, 2009, 381, 1-18. 
44. P. J. W. Schuijl, H. J. T. Bos and L. Brandsma, Recl Trav Chim Pay-B, 1969, 88, 597-
&. 
45. M. Lachia, F. Denes, F. Beaufils and P. Renaud, Org Lett, 2005, 7, 4103-4106. 
46. E. F. Choo, J. Boggs, C. Q. Zhu, J. W. Lubach, N. D. Catron, G. Jenkins, A. J. Souers 
and R. Voorman, Drug Metab Dispos, 2014, 42, 207-212. 
47. F. Danhier, N. Lecouturier, B. Vroman, C. Jerome, J. Marchand-Brynaert, O. Feron 
and V. Preat, Journal of Controlled Release, 2009, 133, 11-17. 
48. R. K. Maheshwari, A. K. Singh, J. Gaddipati and R. C. Srimal, Life Sci, 2006, 78, 
2081-2087. 
49. M. M. Yallapu, M. Jaggi and S. C. Chauhan, Drug Discov Today, 2012, 17, 71-80. 
50. Z. M. Song, W. X. Zhu, N. Liu, F. Y. Yang and R. L. Feng, International Journal of 
Pharmaceutics, 2014, 471, 312-321. 
51. M. L. Gou, K. Men, H. S. Shi, M. L. Xiang, J. A. Zhang, J. Song, J. L. Long, Y. Wan, 
F. Luo, X. Zhao and Z. Y. Qian, Nanoscale, 2011, 3, 1558-1567. 
52. L. Y. Zhao, J. C. Du, Y.W. Duan, Y. N. Zang, H. S. Zhang, C. F. Yang, F. L. Cao, G. 
X. Zhai, Colloid. Surface B 2012, 97, 101-108. 
53. M. Lopez-Lazaro, Mol Nutr Food Res, 2008, 52, S103-S127. 
 
  
39 
 
PCL-PEG graft copolymers with tunable amphiphilicity as efficient drug 
delivery systems  
A. Al Samad, 
a,b
 A. Bethry,
 a
 E. Koziolová, 
c
 M. Netopilík, 
c
 T. Etrych, 
c
 Y. Bakkour, 
b
 J. 
Coudane,
 a
 F. El Omar, 
b
 B. Nottelet 
a
* 
 
a
 Institut des Biomolécules Max Mousseron (IBMM) UMR 5247 CNRS-Université 
Montpellier-ENSCM, Faculté de Pharmacie, 15, avenue Charles Flahault BP14491, 34093 
Montpellier cedex 5, France 
E-mail: benjamin.nottelet@umontpellier.fr 
b
 Laboratory of Applied Chemistry, Doctoral School of Sciences and Technology, Lebanese 
University, Lebanon 
c
 Institute of Macromolecular Chemistry AS CR, v.v.i., Heyrovsky Sq. 2, 162 06 Prague 6, 
Czech Republic 
  
40 
 
 
Scheme S1. Schematic representation of the preparation of the PCL-g-PEG copolymers by 
thiol-yne approach. 
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Figure S1. Excitation spectra of pyrene (em = 371 nm) as a function of the concentration of 
PCL-g-PEG2k3.2.  
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Figure S2a. Fit curve for the curcumin release from PCL-g-PEG0.7k1.9 (software Curve Expert1.4) 
 
Figure S2b. Fit curve for the curcumin release from PCL-g-PEG2k2.6 (software Curve Expert1.4) 
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Figure S2c. Fit curve for the curcumin release from PCL-g-PEG2k4.9 (software Curve Expert1.4) 
 
 
Figure S2d. Extrapolation of fit curves over 100 days for the release curcumin from PCL-g-PEG 
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Figure S3. Viability of MCF-7 cells in different media. The grey bar represent the control in 
culture medium, green bars represent the culture medium supplemented with PBS (1.5% to 
15%) and purple bars represent the culture medium supplemented with DMSO (0.05% and 
0.1%) 
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Figure S4. Viability of MCF-7 cells in the presence of non-loaded nanoaggregates. The 
concentration of blank nanoaggregates used in this assay was equal to the concentration of 
loaded nanoaggregates used to reach curcumin concentrations of 0.18 and 18 µg/L. (Data are 
expressed as means ± SD and correspond to measurements in triplicate) 
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Table S1. SEC analysis of PCL-g-PEG during degradation at 37ᵒc in PBS. (Mn values 
expressed as means ± SD and correspond to measurements in triplicate 
Copolymer /  
Time 
PCL-g-PEG0.7k1.2 PCL-g-PEG2k5.4 
Mn (g/mol) Ð Mn (g/mol) Ð 
T0 19400 ± 1400 2,1 ± 0,2 27000 ± 3700 1,6 ± 0,2 
 
1 W 27000 ± 1150 2,6 ± 0,2 20000 ± 7200 1,5 ± 0,1 
1700 ± 100 1,2 ± 0,2 
1 M 27500 ± 1800 2,8 ± 0,1 17400 ± 5500 1,2 ± 0,1 
1200 1,2 2900 ± 100 1,0 ± 0,1 
3 M 16400 ± 500 1,9 ± 0,1 37100 ± 2300 1,4 ± 0,1 
960 ± 60 1,1 2600 ± 100 1,0 ± 0,1 
6 M 12800 ± 400 1,6 ± 0,1 26000 ± 4900 1,4 
900 ± 50 1,1 2500 ± 100 1,1 
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Table S2. Chemical structure and solubility parameters of tested APIs 
Drug Chemical structure Solubility  logP* 
Paclitaxel 
 
1 mg/L  
Zhang JA. et al. Eur J 
Pharm Biopharm 2005, 
59, 177. 
3.95 
ABT-199 
(Venetoclax) 
 
< 0.4 mg/L 
3. Choo E.F. et al. Drug 
Metab Dispos 2014, 42, 
207. 
8.05 
Curcumin 
 
0.6 mg/L 
B.T. Kurien et al. Assay 
Drug Dev Technol, 2007, 
5, 567.  
3.07 
Elacridar 
 
120 µg/L 
Sane R. et al. J Pharm Sci 
2013, 102, 1343. 
4.43 
Dexamethasone 
 
0.1 g/L 
Dilova V. et al. Boll Chim 
Farm 2004,143, 20. 
2.03 
Clofazimine 
 
0.3 g/L 
Peters K. et al. J. 
Antimicrob. Chemother. 
2000, 45, 77. 
7.46 
*From Scifinder, calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 
 
 
